Akero Therapeutics Inc AKRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKRO is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
-
Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.
-
Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders
-
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
-
Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Shareholders
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
Trading Information
- Previous Close Price
- $20.51
- Day Range
- $20.39–21.05
- 52-Week Range
- $11.25–58.38
- Bid/Ask
- $20.76 / $21.60
- Market Cap
- $1.43 Bil
- Volume/Avg
- 789,256 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 52
- Website
- https://www.akerotx.com
Comparables
Valuation
|
Metric
|
AKRO
|
CBAY
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.14 | 12.65 | 1.63 |
Price/Sales | — | 111.01 | 477.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
AKRO
CBAY
PLRX
Financial Strength
|
Metric
|
AKRO
|
CBAY
|
PLRX
|
|---|---|---|---|
Quick Ratio | 28.75 | 10.70 | 17.43 |
Current Ratio | 29.27 | 10.96 | 17.72 |
Interest Coverage | −55.78 | −5.27 | −145.34 |
Quick Ratio
AKRO
CBAY
PLRX
Profitability
|
Metric
|
AKRO
|
CBAY
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −25.18% | −30.06% | −22.68% |
Return on Equity (Normalized) | −27.49% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −30.46% | −30.87% | −28.46% |
Return on Assets
AKRO
CBAY
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfvsxqjdl | Ktljx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qfhqlmk | Gktzwh | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Svzzxqb | Ddpkq | $98.1 Bil | |
MRNA
| Moderna Inc | Tjfvgywy | Xxny | $39.1 Bil | |
ARGX
| argenx SE ADR | Mycbwzn | Npwl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Zmdwgznnv | Jvtd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xrxnnvcz | Ycgflpf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lknkmtv | Kllpdd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxnhhthrk | Mnpzljy | $12.5 Bil | |
INCY
| Incyte Corp | Pslynswpr | Fbqlclx | $11.9 Bil |